Last month, Granules said it had received 11 observations from INFARMED for its Gagillapur facility. INFARMED had conducted a renewal inspection of the facility.
"After submission of the responses to the audit observation, re-inspection of the said facility was conducted by INFARMED from January 31 to February 2. We are pleased to inform that re-inspection was completed successfully," Granules India said in a regulatory filing.
The plant manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages.
Shares of Granules India were trading 7.10 per cent higher at Rs 124.50 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content